Edition:
United States

United Therapeutics Corp (UTHR.O)

UTHR.O on Nasdaq

121.01USD
29 Jul 2016
Change (% chg)

$2.02 (+1.70%)
Prev Close
$118.99
Open
$118.97
Day's High
$122.23
Day's Low
$118.18
Volume
868,769
Avg. Vol
691,845
52-wk High
$172.39
52-wk Low
$97.52

UTHR.O

Chart for UTHR.O

About

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. Its therapeutic products and product candidates include Prostacyclin Analogues, Phosphodiesterase Type 5 (PDE-5) Inhibitor and... (more)

Overall

Beta: 1.62
Market Cap(Mil.): $5,260.04
Shares Outstanding(Mil.): 43.47
Dividend: --
Yield (%): --

Financials

  UTHR.O Industry Sector
P/E (TTM): 5.88 42.29 39.28
EPS (TTM): 20.58 -- --
ROI: 65.13 -8.76 14.40
ROE: 70.41 -8.92 15.47

BRIEF-United Therapeutics qtrly non-gaap EPS $ 3.02

* United therapeutics corporation reports first quarter 2016 financial results

Apr 28 2016

BRIEF-SteadyMed says U.S. Patent and Trademark office has initiated proceeding against patent owned by United Therapeutics

* U.S. Patent and trademark office has initiated IPR proceeding against U.S. Patent No. 8,497,393 owned by United Therapeutics Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Apr 11 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : S&P Capital IQ Quantitative Report
$104.00
Provider : Reuters Investment Profile
$20.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : Stock Traders Daily
$20.00
Provider : New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.